Immunome CBO Kinney Horn sells $2.27m in company stock

Immunome CBO Kinney Horn sold 90,616 shares for $2.27M (avg. $25.09) under a Rule 10b5-1 plan, after the stock surged 162% over the past year and trades near a 52-week high of $27.65. Offsetting that, the FDA accepted Immunome’s New Drug Application for varegacestat based on Phase 3 RINGSIDE results showing an 84% reduction in risk of disease progression or death vs. placebo, and H.C. Wainwright reiterated a $40 Buy price target. The FDA milestone and trial dosing progress are likely to support sentiment despite the insider sell.

Analysis

The insider sale is more important as supply than as signal. It was mechanically sourced from option exercise and executed under a pre-set plan, so it does not read like informed selling; the bigger issue is that a high-beta biotech trading near peak levels can absorb only so much stock before momentum exhausts. In the next 1-4 weeks, the stock likely trades more on biotech risk appetite and whether the company avoids a financing overhang than on the disposition itself.

The more material point is competitive economics: a second entrant in a niche rare-disease market rarely gets full-margin pricing power unless it is meaningfully better on tolerability, dosing, or label breadth. If investors are extrapolating the regulatory filing into a large standalone franchise, that is probably too generous; the first mover already sets the commercial reference point, so IMNM needs differentiation, not just approval path progression. That makes the next 1-3 months a re-rating test rather than a straight-line continuation story.

Contrarian view: the move may be overextended if the market is treating the filing acceptance as de-risked revenue. The real falsifier for the bull case is either a clean competitor comparison that shows no meaningful efficacy/safety edge, or any capital raise before the review clock runs out. Over 6-18 months, the platform value sits in the early programs, but those are still too far away to support a full multiple today; near-term value is mostly binary regulatory optionality, not durable cash flow.

Key Decisions for Investors

• Avoid initiating fresh long IMNM here; wait for either a post-rally pullback or a confirmed regulatory milestone. Risk/reward is poor at elevated volatility because the stock already discounts a lot of the good news.
• If already long IMNM, trim 25-50% into strength and keep the remainder only if it can hold above the prior breakout zone on volume for 2-3 weeks. Falsifier: a close back below the 20-day moving average after the next catalyst.
• Pair trade: long SWTX / short IMNM over the next 1-3 months. Thesis: the incumbent has clearer commercial visibility, while IMNM still needs to prove differentiation before the market assigns durable franchise value.
• For options traders, consider a small IMNM put spread into the next volatility event rather than outright short stock. Time horizon 30-60 days; this expresses valuation compression without taking unlimited binary regulatory risk.